Alzamend Neuro Reports $1.0 Million Net Loss for Quarter, Advances Clinical Trials

Alzamend Neuro, Inc. has reported its financial results for the three and six months ended October 31, 2025, revealing a net loss of $1.0 million for the quarter and $3.7 million for the half-year period. This represents a decrease in net loss of approximately 26% for the quarter compared to a loss of $1.4 million in the same period last year, and a 59% increase in loss for the six-month period compared to $2.3 million in the prior year. The company has not generated any revenue during these periods, consistent with its ongoing focus on the clinical development of its two product candidates, AL001 and ALZN002.

Total operating expenses for the three months ended October 31, 2025, were $998,109, down 27% from $1.36 million in the same quarter of 2024. The reduction in expenses was primarily driven by a significant decrease in research and development costs, which fell by 43% to $176,283, and a 22% decline in general and administrative expenses, which totaled $821,826. For the six-month period, total operating expenses increased by 59% to $3.7 million, largely due to a substantial rise in research and development expenses, which surged to $1.9 million from $518,000 in the prior year.

In terms of strategic developments, Alzamend has made notable progress in its clinical trials. The company is advancing its lead product candidate, AL001, which is designed for the treatment of Alzheimer’s, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The Phase IIA clinical trial for AL001 was completed in March 2023, and the company is now preparing to initiate five additional clinical trials to further evaluate the product's efficacy. Additionally, Alzamend has partnered with Massachusetts General Hospital to conduct these trials, indicating a strategic move to enhance its clinical capabilities.

As of October 31, 2025, Alzamend reported total assets of $5.1 million, an increase from $4.6 million as of April 30, 2025. The company’s cash position improved to $4.4 million, up from $3.9 million at the end of the previous fiscal period. However, the company continues to face challenges related to its accumulated deficit, which now stands at $62.2 million. Alzamend has indicated that it will need to raise additional capital to fund its ongoing operations and clinical development activities, as it anticipates continued net losses in the foreseeable future.

Looking ahead, Alzamend's management has expressed the need for substantial additional funding to support its clinical development and operational needs. The company plans to pursue financing through public equity, private equity, and debt instruments. The successful execution of its clinical trials and the ability to secure necessary funding will be critical for Alzamend as it seeks to bring its innovative therapies to market and address the significant unmet medical needs in the treatment of neurodegenerative diseases.